Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
O94766
UPID:
B3GA3_HUMAN
Alternative names:
Beta-1,3-glucuronyltransferase 3; Glucuronosyltransferase I; UDP-GlcUA:Gal beta-1,3-Gal-R glucuronyltransferase
Alternative UPACC:
O94766; B7ZAB3; Q96I06; Q9UEP0
Background:
Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3, also known as Beta-1,3-glucuronyltransferase 3, plays a crucial role in glycosaminoglycans biosynthesis. It is pivotal in forming the linkage tetrasaccharide in heparan sulfate and chondroitin sulfate, transferring a glucuronic acid moiety to the common linkage region trisaccharide. This enzyme exhibits strict specificity for its substrate, highlighting its unique function in the biosynthesis pathway.
Therapeutic significance:
The enzyme's association with Multiple joint dislocations, short stature, and craniofacial dysmorphism with or without congenital heart defects underscores its therapeutic significance. Understanding the role of Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3 could open doors to potential therapeutic strategies for treating this autosomal recessive disease.